tetano
Editor, Senior Moderator
Virol J
. 2021 Mar 11;18(1):54.
doi: 10.1186/s12985-021-01522-2.
Assessment of dengue and COVID-19 antibody rapid diagnostic tests cross-reactivity in Indonesia
Marsha S Santoso[SUP] 1 [/SUP], Sri Masyeni[SUP] 2 [/SUP], Sotianingsih Haryanto[SUP] 3 [/SUP], Benediktus Yohan[SUP] 1 [/SUP], Martin L Hibberd[SUP] 4 [/SUP], R Tedjo Sasmono[SUP] 5 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic remains ongoing around the world, including in areas where dengue is endemic. Dengue and COVID-19, to some extent, have similar clinical and laboratory features, which can lead to misdiagnosis, delayed treatment and patient's isolation. The use of rapid diagnostic tests (RDT) is easy and convenient for fast diagnosis, however there may be issues with cross-reactivity with antibodies for other pathogens.
Methods: We assessed the possibility of cross-reactivity between SARS-CoV-2 and dengue antibodies by: (1) testing five brands of COVID-19 IgG / IgM RDTs on 60 RT-PCR-confirmed dengue samples; (2) testing 95 RT-PCR-confirmed COVID-19 samples on dengue RDT; and (3) testing samples positive for COVID-19 IgG and/or IgM on dengue RDT.
Results: We observed a high specificity across all five brands of COVID-19 RDTs, ranging from 98.3 to 100%. Out of the confirmed COVID-19 samples, one patient tested positive for dengue IgM only, another tested positive for dengue IgG only. One patient tested positive for dengue IgG, IgM, and NS1, suggesting a co-infection. In COVID-19 IgG and/or IgM samples, 6.3% of COVID-19 IgG-positive samples also tested positive for dengue IgG, while 21.1% of COVID-19 IgM-positive samples also tested positive for dengue IgG.
Conclusion: Despite the high specificity of the COVID-19 RDT, we observed cross-reactions and false-positive results between dengue and COVID-19. Dengue and COVID-19 co-infection was also found. Health practitioners in dengue endemic areas should be careful when using antibody RDT for the diagnosis of dengue during the COVID-19 pandemic to avoid misdiagnosis.
Keywords: COVID-19; Cross-reactivity; Dengue; IgG; IgM; RDT; Specificity.
. 2021 Mar 11;18(1):54.
doi: 10.1186/s12985-021-01522-2.
Assessment of dengue and COVID-19 antibody rapid diagnostic tests cross-reactivity in Indonesia
Marsha S Santoso[SUP] 1 [/SUP], Sri Masyeni[SUP] 2 [/SUP], Sotianingsih Haryanto[SUP] 3 [/SUP], Benediktus Yohan[SUP] 1 [/SUP], Martin L Hibberd[SUP] 4 [/SUP], R Tedjo Sasmono[SUP] 5 [/SUP]
Affiliations
- PMID: 33706767
- DOI: 10.1186/s12985-021-01522-2
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic remains ongoing around the world, including in areas where dengue is endemic. Dengue and COVID-19, to some extent, have similar clinical and laboratory features, which can lead to misdiagnosis, delayed treatment and patient's isolation. The use of rapid diagnostic tests (RDT) is easy and convenient for fast diagnosis, however there may be issues with cross-reactivity with antibodies for other pathogens.
Methods: We assessed the possibility of cross-reactivity between SARS-CoV-2 and dengue antibodies by: (1) testing five brands of COVID-19 IgG / IgM RDTs on 60 RT-PCR-confirmed dengue samples; (2) testing 95 RT-PCR-confirmed COVID-19 samples on dengue RDT; and (3) testing samples positive for COVID-19 IgG and/or IgM on dengue RDT.
Results: We observed a high specificity across all five brands of COVID-19 RDTs, ranging from 98.3 to 100%. Out of the confirmed COVID-19 samples, one patient tested positive for dengue IgM only, another tested positive for dengue IgG only. One patient tested positive for dengue IgG, IgM, and NS1, suggesting a co-infection. In COVID-19 IgG and/or IgM samples, 6.3% of COVID-19 IgG-positive samples also tested positive for dengue IgG, while 21.1% of COVID-19 IgM-positive samples also tested positive for dengue IgG.
Conclusion: Despite the high specificity of the COVID-19 RDT, we observed cross-reactions and false-positive results between dengue and COVID-19. Dengue and COVID-19 co-infection was also found. Health practitioners in dengue endemic areas should be careful when using antibody RDT for the diagnosis of dengue during the COVID-19 pandemic to avoid misdiagnosis.
Keywords: COVID-19; Cross-reactivity; Dengue; IgG; IgM; RDT; Specificity.